Lidocaine hydrochloride 5% and dextrose 7.5%

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Virtual Booth

Contact Supplier

Access all COS suppliers
Check all USDMF suppliers

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

78 API Suppliers, 13 USDMF, 10 CEP/COS, 3 JDMF, 7 EU WC, 14 KDMF, 28 NDC API, 38 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

6 Drugs in Development

6 Drugs in Development

FINISHED DOSAGE FORMULATIONS

418 FDF Dossiers, 227 FDA Orange Book, 66 Europe, 64 Canada, 17 South Africa, 44 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - 4%, INJECTABLE;INJECTION - 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 2% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 20% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 4% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 0.005MG/ML;0.5%, INJECTABLE;INJECTION - 0.005MG/ML;1%, INJECTABLE;INJECTION - 0.005MG/ML;1.5%, INJECTABLE;INJECTION - 0.005MG/ML;2%, INJECTABLE;INJECTION - 0.01MG/ML;1%, INJECTABLE;INJECTION - 0.01MG/ML;2%, INJECTABLE;INJECTION - 0.02MG/ML;2%, INJECTABLE;INJECTION - 0.5%, INJECTABLE;INJECTION - 1%, INJECTABLE;INJECTION - 1.5%, INJECTABLE;INJECTION - 2%, INJECTABLE;INJECTION - 1%, INJECTABLE;INJECTION - 2%, INJECTABLE;INJECTION - 1%, INJECTABLE;SPINAL - 5%, JELLY;TOPICAL - 2% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 0.02MG BASE/ML;2%, INJECTABLE;INJECTION - EQ 0.01MG BASE/ML;2%

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Evonik, 6 Rochem International Inc, 12 SPI Pharma, 18 DKSH, 1 PMC Isochem, 1 Pharm-RX Chemical, 1 Boai NKY Pharmaceuticals Ltd, 2 Gangwal Healthcare, 18 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 1 Capital Farma, 1 ACG Worldwide, 22 Actylis, 3 Aeon Procare, 3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 43 BASF, 1 Bioplus Life Sciences, 1 BioSpectra, 5 CD Formulation, 1 Clariant, 17 Corel Pharma Chem, 3 Doshion Polyscience, 2 Esteem Industries, 5 Finar, 13 Gangwal Chemicals, 3 Ideal Cures, 2 Ingredion Pharma Solutions, 10 Kerry, 1 Keval Exports, 4 Kima Chemical, 6 Lonza Capsugel, 9 Lubrizol Life Science Health, 9 Microlex e.U, 3 Nanjing Bold Chemical, 2 Nippon Fine Chemical, 2 Nomisma Healthcare, 2 Novo Excipients, 1 Pharmatrans-Sanaq, 4 Pluviaendo, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 21 Roquette, 25 Seppic, 3 Shandong Focus Biotechnology Co., Ltd, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 4 Sigachi Industries, 2 Symrise, 3 The Dow Chemical Company, 2 Valens Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

79 Topical, 67 Solubilizers, 54 Thickeners and Stabilizers, 48 Coating Systems & Additives, 36 Fillers, Diluents & Binders, 34 Emulsifying Agents, 33 Parenteral, 29 Controlled & Modified Release, 25 Film Formers & Plasticizers, 22 Surfactant & Foaming Agents, 21 Rheology Modifiers, 19 Taste Masking, 18 Granulation, 17 Direct Compression, 12 Co-Processed Excipients, 11 Lubricants & Glidants, 10 API Stability Enhancers, 8 Chewable & Orodispersible Aids, 7 Disintegrants & Superdisintegrants, 5 Empty Capsules, 4 Vegetarian Capsules, 4 Coloring Agents, 1 Soft Gelatin

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 60 News #PharmaBuzz

GLOBAL SALES INFORMATION

34 US Medicaid Prescriptions, 58 Regulatory FDF Prices

MARKET PLACE

54 APIs, 15 FDF Dossiers

PATENTS & EXCLUSIVITIES

4 US Patents

4 US Patents

REF. STANDARDS & IMPURITIES

1 EDQM

1 EDQM

Xls

Filters

Company Name

Year

DEALS // DEV.

Country

Sponsor

Therapeutic Area

Study Phase

Deal Type

Product Type

Dosage Form

Lead Product

Target

Filters

Reset Filter

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Aspen Pharmacare Holdings

South Africa

EPSC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Lidocaine Hydrochloride,Inapplicable

Therapeutic Area : Neurology

Study Phase : Approved FDF

Sponsor : Sandoz B2B

Deal Size : $440.0 million

Deal Type : Acquisition

DEALS_DEV

Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third l...

Details : The acquisition strengthens Sandoz’s presence in the hospital channel by complementing the broad Sandoz portfolio and pipeline of hospital generic and biosimilar products in Japan like Lidocaine Hydrochloride.

Product Name : Lidocaine HCl- Generic

Product Type : Other Small Molecule

Upfront Cash : $330.0 million

January 31, 2020

Lead Product(s) : Lidocaine Hydrochloride,Inapplicable

Therapeutic Area : Neurology

Highest Development Status : Approved FDF

Sponsor : Sandoz B2B

Deal Size : $440.0 million

Deal Type : Acquisition

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

02

Chemische Fabrik Berg

Germany

EPSC

Not Confirmed

Lead Product(s) : Lidocaine Hydrochloride,Articaine Hydrochloride,Epinephrine

Therapeutic Area : Dental and Oral Health

Study Phase : Phase IV

Sponsor : Anfomed

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Acceptance and Preference of Lidocaine Gel Compared to Injection Anesthesia After Non Surgical Periodontal Tre...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 27, 2017

Lead Product(s) : Lidocaine Hydrochloride,Articaine Hydrochloride,Epinephrine

Therapeutic Area : Dental and Oral Health

Highest Development Status : Phase IV

Sponsor : Anfomed

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

03

Renascience Pharma

Country

U.S.A

EPSC

Not Confirmed

Find Clinical Drug Pipeline Developments & Deals for Lidocaine hydrochloride 5% and dextrose 7.5%